Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

BACKGROUND: Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab–cilgavimab versus placebo, in patients receiving remdesivir and other standard care. METHODS: In a randomised...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270059/
https://www.ncbi.nlm.nih.gov/pubmed/35817072
http://dx.doi.org/10.1016/S2213-2600(22)00215-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270059/
https://www.ncbi.nlm.nih.gov/pubmed/35817072
http://dx.doi.org/10.1016/S2213-2600(22)00215-6

Ejemplares similares